Top Tweets for #POLBF

8 months ago

$POLB Poolbeg Pharma CEO on POLB001 & GLP-1 trial plans - ICYMI https://t.co/NtbaAYHeqw @PoolbegPharma $POLBF #POLB #POLBF

4

1

0

777

almost 2 years ago

Last week our CEO & CBO presented with @tamzinpiworld. 👁️#POLB Overview 🔬POLB 001 ✅Exclusive option agreement 🏃‍♀️ 2024 momentum If you missed the presentation, you can watch it here: https://t.co/hKT2uBaqN0 #POLBF #PIWORLD #Pharma

0

12

7

0

641

about 2 years ago

$POLB Poolbeg Pharma agrees 12 month option over orphan drug with fast-track potential https://t.co/FtsU4qDVpg @PoolbegPharma $POLBF #POLB #POLBF

0

1

2

0

491

Share_Talk ™

@Share_Talk

about 2 years ago

@PoolbegPharma estimate that by 2030 there will be ~500,000 potential eligible patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL) alone, across the US and EU5. #POLBF $POLBF If all of these patients were to be treated with cancer immunotherapies, the direct costs to the healthcare systems of managing CRS associated with these immunotherapies would be >US$5.5 billion

about 2 years ago

Cancer immunotherapies can only be administered in specialised centres due to the risk of developing CRS - limiting access We estimate that treating 500,000 #cancer patients with immunotherapies may cost healthcare systems >US$5.5 billion to manage #CRS alone. #POLBF $POLBF

PoolbegPharma's tweet photo. Cancer immunotherapies can only be administered in specialised centres due to the risk of developing CRS - limiting access

We estimate that treating 500,000 #cancer patients with immunotherapies may cost healthcare systems >US$5.5 billion to manage #CRS alone.

#POLBF $POLBF https://t.co/dYdS3IyuWp

0

23

14

0

4K

0

6

0

2K

about 2 years ago

Cancer immunotherapies can only be administered in specialised centres due to the risk of developing CRS - limiting access We estimate that treating 500,000 #cancer patients with immunotherapies may cost healthcare systems >US$5.5 billion to manage #CRS alone. #POLBF $POLBF

0

23

14

0

4K

about 2 years ago

$POLB Poolbeg Pharma moves a step closer to locking down IP protection for key asset https://t.co/bIK3vyg2sJ @PoolbegPharma $POLBF #POLB #POLBF

0

1

0

538

over 2 years ago

$POLB Poolbeg Pharma chairman tops up with share purchase https://t.co/vrTlw1LAhN @PoolbegPharma $POLBF #POLB #POLBF

1

2

1

0

1K

over 2 years ago

$POLB Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies https://t.co/9Xx7RcRlRG @PoolbegPharma $POLBF #POLB #POLBF

0

2

1

0

642

over 2 years ago

$POLB Poolbeg Pharma points to independent research that suggests $10bn market for lead asset https://t.co/vKbyaM6UvH @PoolbegPharma $POLBF #POLB #POLBF

0

4

3

0

1K

over 2 years ago

$POLB Poolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assets https://t.co/NE7rzzkjAm @PoolbegPharma $POLBF #POLB #POLBF

0

1

2

0

2K

over 2 years ago

$POLB Poolbeg Pharma announces "very positive" efficacy data for POLB 001 https://t.co/YbHLsfDDbd @PoolbegPharma $POLBF #POLB #POLBF

0

3

1

0

975

over 2 years ago

$POLB Poolbeg Pharma management will look to partner RSV discoveries, says research house https://t.co/i276wUrpDq @PoolbegPharma $POLBF #POLB #POLBF

0

3

1

0

499

over 2 years ago

$POLB Poolbeg hails progress of AI drug discovery programmme https://t.co/P7WpwgEtIf @PoolbegPharma $POLBF #POLB #POLBF

0

2

1

0

559

over 2 years ago

$POLB Poolbeg Pharma to showcase potential of lead asset at prestigious conference https://t.co/AITKbxFhlq @PoolbegPharma $POLBF #POLB #POLBF

0

1

0

461

over 2 years ago

$POLB Poolbeg's lead asset to be in the spotlight at leading medical conference https://t.co/n5r2mQOeLL @PoolbegPharma $POLBF #POLB #POLBF

0

1

0

615